• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Chattem

Chattem

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Active vs. Passive Investing: A Bottom Line

    Chattem's CHTT second-quarter results were in line with our expectations, so our fair value estimate for the shares remains unchanged. The firm is already reaping the benefits of the five brands it acquired from Johnson & Johnson JNJ in early January in the form of sales growth and improving ...

  2. Research and Markets: Global Glycine Industry Report 2015

    Research and Markets: Global Glycine Industry Report 2015

  3. Invest With These Exemplary Management Teams

    These great businesses are undervalued and run by CEOs that are looking out for the best interests of shareholders.

  4. Finding Moats in Big Pharma's Consumer Health Units

    We believe breakups could unlock value for big pharma shareholders.

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.